Maria Lyng - Concepedia

Concepedia

Author

Maria Lyng

University of Southern Denmark

Also Known As

M Lyng, M. Lyng, Maria B Lyng, Maria B. Lyng, Maria Bibi Lyng, Maria Lyng

73

Publications

1.5K

Citations

19

H-Index

35

Concepts

All Affiliations

University of Southern Denmark Odense University Hospital Danish Breast Cancer Cooperative Group Slagelse Hospital Rigshospitalet

ML

About

Maria Lyng is an author at University of Southern Denmark specializing in medicine, radiation oncology, and breast cancer.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	9	9	429
2	Health Sciences	2	2	73
3	Engineering	1	1	152
4	Public Health	1	1	20
5	Biostatistics	1	1	20

Maria Lyng

×

23

Publications

1.5K

Citations

19

H-Index

	Year	Citations
CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women with Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 Trial Meredith M. Regan, Brian Leyland‐Jones, Mark Bouzyk, JNCI Journal of the National Cancer Institute	2012	338
Novel circulating microRNA signature as a potential non‐invasive multi‐marker test in ER‐positive early‐stage breast cancer: A case control study Annette Raskov Kodahl, Maria Lyng, Harald Binder, Molecular Oncology	2014	185
Chromosome 1q21.3 amplification is a trackable biomarker and actionable target for breast cancer recurrence Jian Yuan Goh, Min Feng, Wenyu Wang, Nature Medicine ChromatinSystems BiologyBreast Cancer RecurrenceEngineeringBreast Oncology	2017	152
Identification of genes for normalization of real-time RT-PCR data in breast carcinomas Maria Lyng, Anne‐Vibeke Lænkholm, Niels Pallisgaard, BMC Cancer	2008	113
The miRNA-200 family and miRNA-9 exhibit differential expression in primary versus corresponding metastatic tissue in breast cancer Karina Gravgaard Thomsen, Maria Lyng, Anne‐Vibeke Lænkholm, Breast Cancer Research and Treatment Breast OncologyMetastatic TissueBreast CancerMirna-200 FamilyMicrorna Detection	2012	96
Determination of HER2 phosphorylation at tyrosine 1221/1222 improves prediction of poor survival for breast cancer patients with hormone receptor-positive tumors Thomas Frogne, Anne‐Vibeke Lænkholm, Maria Lyng, Breast Cancer Research	2009	72
High CDK6 Protects Cells from Fulvestrant-Mediated Apoptosis and is a Predictor of Resistance to Fulvestrant in Estrogen Receptor–Positive Metastatic Breast Cancer Carla L. Alves, Daniel Eliáš, Maria Lyng, Clinical Cancer Research	2016	67
Global MicroRNA Expression Profiling of High-Risk ER+ Breast Cancers from Patients Receiving Adjuvant Tamoxifen Mono-Therapy: A DBCG Study Maria Lyng, Anne‐Vibeke Lænkholm, Rolf Søkilde, PLoS ONE	2012	60
SNAI2 upregulation is associated with an aggressive phenotype in fulvestrant-resistant breast cancer cells and is an indicator of poor response to endocrine therapy in estrogen receptor-positive metastatic breast cancer Carla L. Alves, Daniel Eliáš, Maria Lyng, Breast Cancer Research	2018	43
Coexisting genomic aberrations associated with lymph node metastasis in breast cancer Li Bao, Zhaoyang Qian, Maria Lyng, Journal of Clinical Investigation Breast OncologyOncologyGenomic AberrationsTumor HeterogeneityMedicine	2018	41

Page 1